organic compounds
8,15-Dioxa-10,13-diazatetracyclo[14.4.0.02,7.09,14]icosa-1(16),2,4,6,9(14),10,12,17,19-nonaene
aCentre of Advanced Study in Crystallography and Biophysics, University of Madras, Guindy Campus, Chennai 600 025, India, and bDepartment of Organic Chemistry, University of Madras, Guindy Campus, Chennai 600 025, India
*Correspondence e-mail: shirai2011@gmail.com
The 16H10N2O2, contains one half-molecule, the complete molecule being generated by twofold rotation symmetry. The plane of the pyrazine ring forms a dihedral angle of 64.87 (6)° with that of the benzene ring, and the planes of the two benzene rings are inclined to one another by 54.20 (6)°. The O atom deviates from the plane of the benzene ring by 0.1549 (8) Å. There are no significant intermolecular interactions in the crystal.
of the title compound, CRelated literature
For applications of the pyrazine ring system in drug development, see: Du et al. (2009); Dubinina et al. (2006); Ellsworth et al. (2007); Mukaiyama et al. (2007). For background to the fluorescence properties of related compounds, see: Kawai et al. (2001); Abdullah (2005) and for their biological activity, see: Seitz et al. (2002); Temple et al. (1970). For a related structure, see: Nasir et al. (2010).
Experimental
Crystal data
|
Data collection: APEX2 (Bruker, 2008); cell SAINT (Bruker, 2008); data reduction: SAINT; program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEP-3 for Windows (Farrugia, 2012) and Mercury (Macrae et al., 2008); software used to prepare material for publication: SHELXL97 and PLATON (Spek, 2009).
Supporting information
https://doi.org/10.1107/S1600536813011318/su2586sup1.cif
contains datablocks global, I. DOI:Structure factors: contains datablock I. DOI: https://doi.org/10.1107/S1600536813011318/su2586Isup2.hkl
Supporting information file. DOI: https://doi.org/10.1107/S1600536813011318/su2586Isup3.cml
To a stirred solution of Cs2CO3(15 mmol) in CH3CN (5 mL), was added dropwise independently a solution of corresponding diol (10 mmol) in CH3CN (25 mL) and a solution of 2,3-dichloropyrazine (10 mmol) in CH3CN (25 mL). The reaction mixture was stirred at reflux for 12 h. The reaction mixture was allowed to cool to room temperature and then poured into water (200 mL), and extracted with CH2Cl2 (2X100 mL). The combined organic layers were washed with water (100 mL), brine (50 mL) and dried over Na2SO4. The solvent was evaporated and the crude product was purified by
with CHCl3 as an to give the title compound. Single crystals suitable for X-ray diffraction were obtained by slow evaporation of a solution of the title compound in hexane at room temperature.The hydrogen atoms were placed in calculated positions and refined in the riding model approximation: C—H = 0.93 Å with Uiso(H) = 1.2Ueq(C).
The pyrazine ring system is a useful structural element in medicinal chemistry and has found broad applications in drug development which can be used as antiproliferative agent (Dubinina et al., 2006), potent CXCR3 antagonists (Du et al., 2009),CB1 antagonists (Ellsworth et al., 2007) and c-Src inhibitory (Mukaiyama et al., 2007). On-going structural studies of heterocyclic N-containing derivatives (Nasir et al., 2010) are motivated by an investigation of their fluorescence properties (Kawai et al., 2001; Abdullah, 2005). Pyrazine derivatives were shown to display antimycobacterial (Seitz et al., 2002) and potential antimalarial (Temple et al., 1970) activities. In view of different applications of this class of compounds, we have undertaken the
determination of the title compound.The title compound, Fig. 1, contains one half molecule in the
the complete molecule is generated by a two-fold rotation axis, about [010]; symmetry code:(i) -x+1, y, -z+1/2.The central pyrazine ring (C1/N1/C2/C1i/N1i/C2i) forms a dihedral angle of 64.87 (6) ° with the phenyl ring (C3-C8). The dihedral angle between the symmetry related phenyl rings (C3-C8) and (C3i-C8i) is 54.20 (6) °. The deviation of the atom O1 from the phenyl ring (C3-C8) is 0.1549 (8) Å.
In the crystal, there are no significant intermolecular interactions present.
For applications of the pyrazine ring system in drug development, see: Du et al. (2009); Dubinina et al. (2006); Ellsworth et al. (2007); Mukaiyama et al. (2007). For background to the fluorescence properties of related compounds, see: Kawai et al. (2001); Abdullah (2005) and for their biological activity, see: Seitz et al.(2002); Temple et al. (1970). For a related structure, see: Nasir et al. (2010).
Data collection: APEX2 (Bruker, 2008); cell
SAINT (Bruker, 2008); data reduction: SAINT (Bruker, 2008); program(s) used to solve structure: SHELXS97 (Sheldrick, 2008); program(s) used to refine structure: SHELXL97 (Sheldrick, 2008); molecular graphics: ORTEP-3 for Windows (Farrugia, 2012) and Mercury (Macrae et al., 2008); software used to prepare material for publication: SHELXL97 (Sheldrick, 2008) and PLATON (Spek, 2009).Fig. 1. The molecular structure of the title molecule, with atom labelling (symmetry code: (a) -x+1, y, -z+1/2). Displacement ellipsoids are drawn at the 30% probability level. |
C16H10N2O2 | F(000) = 544 |
Mr = 262.26 | Dx = 1.426 Mg m−3 |
Orthorhombic, Pbcn | Mo Kα radiation, λ = 0.71073 Å |
Hall symbol: -P 2n 2ab | Cell parameters from 1502 reflections |
a = 14.429 (3) Å | θ = 2.5–28.3° |
b = 10.162 (2) Å | µ = 0.10 mm−1 |
c = 8.3313 (18) Å | T = 293 K |
V = 1221.6 (4) Å3 | Block, colourless |
Z = 4 | 0.30 × 0.25 × 0.20 mm |
Bruker SMART APEXII area-detector diffractometer | 1502 independent reflections |
Radiation source: fine-focus sealed tube | 1226 reflections with I > 2σ(I) |
Graphite monochromator | Rint = 0.029 |
ω and φ scans | θmax = 28.3°, θmin = 2.5° |
Absorption correction: multi-scan (SADABS; Bruker, 2008) | h = −18→19 |
Tmin = 0.972, Tmax = 0.981 | k = −5→13 |
6082 measured reflections | l = −7→10 |
Refinement on F2 | Secondary atom site location: difference Fourier map |
Least-squares matrix: full | Hydrogen site location: inferred from neighbouring sites |
R[F2 > 2σ(F2)] = 0.033 | H-atom parameters constrained |
wR(F2) = 0.106 | w = 1/[σ2(Fo2) + (0.0544P)2 + 0.1721P] where P = (Fo2 + 2Fc2)/3 |
S = 1.03 | (Δ/σ)max < 0.001 |
1502 reflections | Δρmax = 0.22 e Å−3 |
92 parameters | Δρmin = −0.13 e Å−3 |
0 restraints | Extinction correction: SHELXL97 (Sheldrick, 2008), Fc*=kFc[1+0.001xFc2λ3/sin(2θ)]-1/4 |
Primary atom site location: structure-invariant direct methods | Extinction coefficient: 0.012 (3) |
C16H10N2O2 | V = 1221.6 (4) Å3 |
Mr = 262.26 | Z = 4 |
Orthorhombic, Pbcn | Mo Kα radiation |
a = 14.429 (3) Å | µ = 0.10 mm−1 |
b = 10.162 (2) Å | T = 293 K |
c = 8.3313 (18) Å | 0.30 × 0.25 × 0.20 mm |
Bruker SMART APEXII area-detector diffractometer | 1502 independent reflections |
Absorption correction: multi-scan (SADABS; Bruker, 2008) | 1226 reflections with I > 2σ(I) |
Tmin = 0.972, Tmax = 0.981 | Rint = 0.029 |
6082 measured reflections |
R[F2 > 2σ(F2)] = 0.033 | 0 restraints |
wR(F2) = 0.106 | H-atom parameters constrained |
S = 1.03 | Δρmax = 0.22 e Å−3 |
1502 reflections | Δρmin = −0.13 e Å−3 |
92 parameters |
Geometry. All esds (except the esd in the dihedral angle between two l.s. planes) are estimated using the full covariance matrix. The cell esds are taken into account individually in the estimation of esds in distances, angles and torsion angles; correlations between esds in cell parameters are only used when they are defined by crystal symmetry. An approximate (isotropic) treatment of cell esds is used for estimating esds involving l.s. planes. |
Refinement. Refinement of F2 against ALL reflections. The weighted R-factor wR and goodness of fit S are based on F2, conventional R-factors R are based on F, with F set to zero for negative F2. The threshold expression of F2 > 2sigma(F2) is used only for calculating R-factors(gt) etc. and is not relevant to the choice of reflections for refinement. R-factors based on F2 are statistically about twice as large as those based on F, and R- factors based on ALL data will be even larger. |
x | y | z | Uiso*/Ueq | ||
C1 | 0.53624 (10) | 1.14890 (12) | 0.19682 (18) | 0.0623 (4) | |
H1 | 0.5600 | 1.2289 | 0.1616 | 0.075* | |
C2 | 0.53746 (8) | 0.92738 (11) | 0.19677 (13) | 0.0426 (3) | |
C3 | 0.60493 (7) | 0.71770 (11) | 0.24296 (13) | 0.0395 (3) | |
C4 | 0.54878 (7) | 0.61036 (10) | 0.27797 (12) | 0.0390 (3) | |
C5 | 0.58736 (8) | 0.50933 (12) | 0.36919 (14) | 0.0480 (3) | |
H5 | 0.5523 | 0.4349 | 0.3922 | 0.058* | |
C6 | 0.67748 (9) | 0.51846 (14) | 0.42609 (16) | 0.0568 (4) | |
H6 | 0.7020 | 0.4509 | 0.4883 | 0.068* | |
C7 | 0.73073 (8) | 0.62674 (15) | 0.39094 (15) | 0.0594 (4) | |
H7 | 0.7908 | 0.6328 | 0.4305 | 0.071* | |
C8 | 0.69529 (8) | 0.72654 (12) | 0.29713 (15) | 0.0505 (3) | |
H8 | 0.7317 | 0.7989 | 0.2706 | 0.061* | |
N1 | 0.57395 (7) | 1.03683 (10) | 0.14200 (14) | 0.0546 (3) | |
O1 | 0.57275 (5) | 0.81298 (8) | 0.13462 (9) | 0.0446 (2) |
U11 | U22 | U33 | U12 | U13 | U23 | |
C1 | 0.0751 (9) | 0.0430 (6) | 0.0688 (9) | −0.0077 (6) | −0.0246 (6) | 0.0065 (6) |
C2 | 0.0464 (6) | 0.0431 (6) | 0.0383 (6) | −0.0018 (4) | −0.0088 (4) | 0.0017 (4) |
C3 | 0.0383 (5) | 0.0458 (5) | 0.0344 (5) | 0.0021 (4) | 0.0021 (4) | −0.0019 (4) |
C4 | 0.0382 (5) | 0.0429 (5) | 0.0357 (5) | 0.0033 (4) | 0.0052 (4) | −0.0026 (4) |
C5 | 0.0498 (6) | 0.0476 (6) | 0.0467 (6) | 0.0092 (5) | 0.0103 (5) | 0.0029 (5) |
C6 | 0.0547 (7) | 0.0697 (8) | 0.0461 (6) | 0.0241 (6) | 0.0024 (5) | 0.0049 (6) |
C7 | 0.0417 (6) | 0.0870 (10) | 0.0496 (7) | 0.0130 (6) | −0.0066 (5) | −0.0073 (7) |
C8 | 0.0394 (6) | 0.0623 (7) | 0.0497 (7) | −0.0040 (5) | −0.0005 (5) | −0.0078 (6) |
N1 | 0.0593 (6) | 0.0495 (6) | 0.0548 (6) | −0.0094 (5) | −0.0118 (5) | 0.0090 (5) |
O1 | 0.0486 (5) | 0.0467 (4) | 0.0384 (4) | −0.0009 (3) | 0.0040 (3) | 0.0041 (3) |
C1—N1 | 1.3423 (17) | C4—C5 | 1.3935 (16) |
C1—C1i | 1.371 (3) | C4—C4i | 1.483 (2) |
C1—H1 | 0.9300 | C5—C6 | 1.3871 (17) |
C2—N1 | 1.3124 (15) | C5—H5 | 0.9300 |
C2—O1 | 1.3707 (14) | C6—C7 | 1.374 (2) |
C2—C2i | 1.398 (2) | C6—H6 | 0.9300 |
C3—C8 | 1.3826 (15) | C7—C8 | 1.3787 (18) |
C3—C4 | 1.3897 (15) | C7—H7 | 0.9300 |
C3—O1 | 1.4029 (13) | C8—H8 | 0.9300 |
N1—C1—C1i | 121.95 (8) | C6—C5—H5 | 119.6 |
N1—C1—H1 | 119.0 | C4—C5—H5 | 119.6 |
C1i—C1—H1 | 119.0 | C7—C6—C5 | 120.33 (12) |
N1—C2—O1 | 116.01 (10) | C7—C6—H6 | 119.8 |
N1—C2—C2i | 122.05 (7) | C5—C6—H6 | 119.8 |
O1—C2—C2i | 121.79 (6) | C6—C7—C8 | 120.18 (11) |
C8—C3—C4 | 122.16 (11) | C6—C7—H7 | 119.9 |
C8—C3—O1 | 118.51 (10) | C8—C7—H7 | 119.9 |
C4—C3—O1 | 118.93 (9) | C7—C8—C3 | 119.14 (11) |
C3—C4—C5 | 117.38 (10) | C7—C8—H8 | 120.4 |
C3—C4—C4i | 119.18 (8) | C3—C8—H8 | 120.4 |
C5—C4—C4i | 123.41 (8) | C2—N1—C1 | 115.99 (12) |
C6—C5—C4 | 120.77 (12) | C2—O1—C3 | 117.73 (8) |
C8—C3—C4—C5 | −0.82 (16) | C4—C3—C8—C7 | −0.97 (17) |
O1—C3—C4—C5 | 171.84 (9) | O1—C3—C8—C7 | −173.66 (10) |
C8—C3—C4—C4i | 177.25 (11) | O1—C2—N1—C1 | 176.77 (10) |
O1—C3—C4—C4i | −10.09 (16) | C2i—C2—N1—C1 | 1.3 (2) |
C3—C4—C5—C6 | 1.84 (16) | C1i—C1—N1—C2 | −0.2 (2) |
C4i—C4—C5—C6 | −176.15 (12) | N1—C2—O1—C3 | 126.38 (10) |
C4—C5—C6—C7 | −1.07 (18) | C2i—C2—O1—C3 | −58.13 (16) |
C5—C6—C7—C8 | −0.78 (19) | C8—C3—O1—C2 | −86.29 (12) |
C6—C7—C8—C3 | 1.78 (18) | C4—C3—O1—C2 | 100.77 (11) |
Symmetry code: (i) −x+1, y, −z+1/2. |
Experimental details
Crystal data | |
Chemical formula | C16H10N2O2 |
Mr | 262.26 |
Crystal system, space group | Orthorhombic, Pbcn |
Temperature (K) | 293 |
a, b, c (Å) | 14.429 (3), 10.162 (2), 8.3313 (18) |
V (Å3) | 1221.6 (4) |
Z | 4 |
Radiation type | Mo Kα |
µ (mm−1) | 0.10 |
Crystal size (mm) | 0.30 × 0.25 × 0.20 |
Data collection | |
Diffractometer | Bruker SMART APEXII area-detector |
Absorption correction | Multi-scan (SADABS; Bruker, 2008) |
Tmin, Tmax | 0.972, 0.981 |
No. of measured, independent and observed [I > 2σ(I)] reflections | 6082, 1502, 1226 |
Rint | 0.029 |
(sin θ/λ)max (Å−1) | 0.666 |
Refinement | |
R[F2 > 2σ(F2)], wR(F2), S | 0.033, 0.106, 1.03 |
No. of reflections | 1502 |
No. of parameters | 92 |
H-atom treatment | H-atom parameters constrained |
Δρmax, Δρmin (e Å−3) | 0.22, −0.13 |
Computer programs: APEX2 (Bruker, 2008), SAINT (Bruker, 2008), SHELXS97 (Sheldrick, 2008), ORTEP-3 for Windows (Farrugia, 2012) and Mercury (Macrae et al., 2008), SHELXL97 (Sheldrick, 2008) and PLATON (Spek, 2009).
Acknowledgements
The authors thank the TBI X-ray facility, CAS in Crystallography and Biophysics, University of Madras, India, for the data collection. TS and DV thank the UGC (SAP–CAS) for the departmental facilties. TS also thanks the DST Inspire program for financial assistance.
References
Abdullah, Z. (2005). Intl J. Chem. Sci. 3, 9–15. CAS Google Scholar
Bruker (2008). APEX2, SAINT and SADABS. Bruker AXS Inc., Madison, Wisconsin, USA. Google Scholar
Du, X. H., Gustin, D. J., Chen, X. Q., Duquette, J., McGee, L. R., Wang, Z. L., Ebsworth, K., Henne, K., Lemon, B., Ma, J., Miao, S. C., Sabalan, E., Sullivan, T. J., Tonn, G., Collins, T. L. & Medina, J. C. (2009). Bioorg. Med. Chem. Lett. 19, 5200–5204. Web of Science CrossRef PubMed CAS Google Scholar
Dubinina, G. G., Platonov, M. O., Golovach, S. M., Borysko, P. O., Tolmachov, A. O. & Volovenko, Y. M. (2006). Eur. J. Med. Chem. 41, 727–737. Web of Science CrossRef PubMed CAS Google Scholar
Ellsworth, B. A., Wang, Y., Zhu, Y. H., Pendri, A., Gerritz, S. W., Sun, C. Q., Carlson, K. E., Kang, L. Y., Baska, R. A., Yang, Y. F., Huang, Q., Burford, N. T., Cullen, M. J., Johnghar, S., Behnia, K., Pelleymounter, M. A., Washburn, W. N. & Ewing, W. R. (2007). Bioorg. Med. Chem. Lett. 17, 3978–3982. Web of Science CrossRef PubMed CAS Google Scholar
Farrugia, L. J. (2012). J. Appl. Cryst. 45, 849–854. Web of Science CrossRef CAS IUCr Journals Google Scholar
Kawai, M., Lee, M. J., Evans, K. O. & Norlund, T. (2001). J. Fluoresc. 11, 23–32. Web of Science CrossRef CAS Google Scholar
Macrae, C. F., Bruno, I. J., Chisholm, J. A., Edgington, P. R., McCabe, P., Pidcock, E., Rodriguez-Monge, L., Taylor, R., van de Streek, J. & Wood, P. A. (2008). J. Appl. Cryst. 41, 466–470. Web of Science CSD CrossRef CAS IUCr Journals Google Scholar
Mukaiyama, H., Nishimura, T., Kobayashi, S., Ozawa, T., Kamada, N., Komatsu, Y., Kikuchi, S., Oonota, H. & Kusama, H. (2007). Bioorg. Med. Chem. Lett. 15, 868–885. CrossRef CAS Google Scholar
Nasir, S. B., Abdullah, Z., Fairuz, Z. A., Ng, S. W. & Tiekink, E. R. T. (2010). Acta Cryst. E66, o2187. Web of Science CSD CrossRef IUCr Journals Google Scholar
Seitz, L. E., Suling, W. J. & Reynolds, R. C. (2002). J. Med. Chem. 45, 5604–5606. Web of Science CrossRef PubMed CAS Google Scholar
Sheldrick, G. M. (2008). Acta Cryst. A64, 112–122. Web of Science CrossRef CAS IUCr Journals Google Scholar
Spek, A. L. (2009). Acta Cryst. D65, 148–155. Web of Science CrossRef CAS IUCr Journals Google Scholar
Temple, C. Jr, Rose, J. D. & Montgomery, J. A. (1970). J. Med. Chem. 13, 1234–1235. CrossRef CAS PubMed Web of Science Google Scholar
This is an open-access article distributed under the terms of the Creative Commons Attribution (CC-BY) Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original authors and source are cited.
The pyrazine ring system is a useful structural element in medicinal chemistry and has found broad applications in drug development which can be used as antiproliferative agent (Dubinina et al., 2006), potent CXCR3 antagonists (Du et al., 2009),CB1 antagonists (Ellsworth et al., 2007) and c-Src inhibitory (Mukaiyama et al., 2007). On-going structural studies of heterocyclic N-containing derivatives (Nasir et al., 2010) are motivated by an investigation of their fluorescence properties (Kawai et al., 2001; Abdullah, 2005). Pyrazine derivatives were shown to display antimycobacterial (Seitz et al., 2002) and potential antimalarial (Temple et al., 1970) activities. In view of different applications of this class of compounds, we have undertaken the crystal structure determination of the title compound.
The title compound, Fig. 1, contains one half molecule in the asymmetric unit; the complete molecule is generated by a two-fold rotation axis, about [010]; symmetry code:(i) -x+1, y, -z+1/2.
The central pyrazine ring (C1/N1/C2/C1i/N1i/C2i) forms a dihedral angle of 64.87 (6) ° with the phenyl ring (C3-C8). The dihedral angle between the symmetry related phenyl rings (C3-C8) and (C3i-C8i) is 54.20 (6) °. The deviation of the atom O1 from the phenyl ring (C3-C8) is 0.1549 (8) Å.
In the crystal, there are no significant intermolecular interactions present.